Stock Ratings / Health Care / LXRX / financials

ABUS (22) IMMX (33) ANL (52) BCAX (45) ⌘ Pro Terminal →

Lexicon Pharmaceuticals Inc. (LXRX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: How profitable is Lexicon Pharmaceuticals Inc. (LXRX)?

In FY 2025 (10-K), LXRX converted $49.8M of revenue into a 99.4% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

$1.48 -0.34% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Lexicon Pharmaceuticals Inc. (LXRX) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $658.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-8.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LXRX)Realized 20D OHLCV Swing Band: ±11.6%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How LXRX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $1.1M

FY24

Rev $6.0M

FY25

Rev $49.8M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$49.8M	98%	-80%	-$50.3M	-$67.9M	-31.5%
FY 2024	$6.0M	89.7%	-80%	-$200.4M	-$179.8M	-45%
FY 2023	$1.1M	92%	-80%	-$177.1M	-$161.9M	-31.5%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LXRX)

✓Walkthrough of LXRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LXRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -8.07%▼ DESCENDING CHANNEL

2026-10-30O $1.47H $1.50L $1.38C $1.48VOL 2.44M

RES: $2.13SUP: $1.32SMA50: $1.89SMA200: $1.88

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LXRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LXRX Butterfly Map → + Track LXRX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LXRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LXRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LXRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LXRX)

Health Care Rank #666 of 1016 ⚔️ ABUS vs LXRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LXRX vs. ABUS, IMMX, ANL, BCAX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lexicon Pharmaceuticals Inc. (LXRX) ranks #666 by composite RQD confidence (39/100, grade D-) and #408 by equity capitalization ($658.5M). Within this direct 5-issuer industry benchmark cohort, LXRX leads on earnings valuation at N/A trailing P/E, while LXRX leads on capital efficiency and profitability with -31.5% ROIC and 96.0% gross margin. ANL currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with LXRX at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LXRX ACTIVE Lexicon Pharmaceuticals Inc.	D-	39/100	—	96.0%	-31.5%	-0.34%	$658.5M	Benchmark Subject
ABUS Arbutus Biopharma Corporation	E	22/100	—	—	-35.0%	-0.93%	$656.0M	/abus-vs-lxrx →
IMMX Immix Biopharma Inc.	E	33/100	—	—	-35.0%	-1.78%	$661.6M	/immx-vs-lxrx →
ANL Adlai Nortye Group Ltd.	D+	52/100	—	—	—	+0.78%	$662.0M	/anl-vs-lxrx →
BCAX Bicara Therapeutics Inc.	D	45/100	—	—	-35.0%	-0.31%	$643.9M	/bcax-vs-lxrx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001062822

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lexicon Pharmaceuticals Inc. (LXRX) reported GAAP revenue of $49.8M (+729.9% vs. FY2024 revenue of $6.0M , and +4386.8% cumulative change since FY2023) , GAAP net income of -$50.3M, operating cash flow of -$67.9M, and free cash flow of -$67.9M (+62.3% YoY). On the balance sheet, LXRX closed FY2025 with $185.0M in total assets against $49.4M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$49.8M	-$50.3M	-$67.9M	-$67.9M	$185.0M	$49.4M
FY2024 (FY)	2024-12-31	$6.0M	-$200.4M	-$178.8M	-$179.8M	$298.4M	$100.3M
FY2023 (FY)	2023-12-31	$1.1M	-$177.1M	-$161.9M	-$161.9M	—	—

3. LXRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LXRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.48 (-0.34% 1D, market cap $658.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LXRX ranks #666 in composite RQD confidence.

How does LXRX compare to ABUS and IMMX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LXRX carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -31.5%. By comparison, ABUS (Arbutus Biopharma Corporation) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $656.0M) and IMMX (Immix Biopharma Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $661.6M). Among the 5-stock peer group, LXRX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LXRX?

Per LXRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001062822), Lexicon Pharmaceuticals Inc. generated $49.8M in revenue (+729.9% YoY), -$50.3M in net income, and -$67.9M in free cash flow against $185.0M in total assets and $49.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LXRX trading relative to its 50-day, 200-day, and 52-week technical levels?

LXRX last traded at $1.48 (-0.34% on volume of 1,772,659 shares), positioning the stock -21.69% below its 50-day simple moving average ($1.89) and -21.28% below its 200-day simple moving average ($1.88). Across its 52-week range of $1.10 to $2.68, LXRX sits at the 24.1% percentile with a 14-day RSI of 29.1 (OVERSOLD (<32)) and an implied next-earnings move of ±11.6% ($1.31 to $1.65).

LXRX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Lexicon Pharmaceuticals Inc. (LXRX)?

In FY 2025 (10-K), LXRX converted $49.8M of revenue into a 99.4% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: LXRX RQD Cockpit LXRX 12M Forecast LXRX Earnings & Move LXRX Dividends & DRIP LXRX Insiders & 13F LXRX Whale Options LXRX Profit Sankey LXRX News & Why